274 related articles for article (PubMed ID: 31030372)
1. Predictive Value of Microdose Pharmacokinetics.
van Nuland M; Rosing H; Huitema ADR; Beijnen JH
Clin Pharmacokinet; 2019 Oct; 58(10):1221-1236. PubMed ID: 31030372
[TBL] [Abstract][Full Text] [Related]
2. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
Van Nuland M; Rosing H; Thijssen B; Burgers JA; Huitema ADR; Marchetti S; Schellens JHM; Beijnen JH
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):929-937. PubMed ID: 31970932
[TBL] [Abstract][Full Text] [Related]
3. Novel strategies for microdose studies using non-radiolabeled compounds.
Maeda K; Sugiyama Y
Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
[TBL] [Abstract][Full Text] [Related]
6. A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens.
van der Heijden L; van Nuland M; Beijnen J; Huitema A; Dorlo T
Clin Transl Sci; 2023 Feb; 16(2):258-268. PubMed ID: 36419385
[TBL] [Abstract][Full Text] [Related]
7. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.
Bosgra S; Vlaming ML; Vaes WH
Clin Pharmacokinet; 2016 Jan; 55(1):1-15. PubMed ID: 26242381
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
[TBL] [Abstract][Full Text] [Related]
9. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
[TBL] [Abstract][Full Text] [Related]
10. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
11. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
12. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
Fujita K; Yoshino E; Kawara K; Maeda K; Kusuhara H; Sugiyama Y; Yokoyama T; Kaneta T; Ishida H; Sasaki Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
[TBL] [Abstract][Full Text] [Related]
13. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.
Garner CR; Park KB; French NS; Earnshaw C; Schipani A; Selby AM; Byrne L; Siner S; Crawley FP; Vaes WH; van Duijn E; deLigt R; Varendi H; Lass J; Grynkiewicz G; Maruszak W; Turner MA
Br J Clin Pharmacol; 2015 Jul; 80(1):157-67. PubMed ID: 25619398
[TBL] [Abstract][Full Text] [Related]
14. The utility of microdosing over the past 5 years.
Lappin G; Garner RC
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1499-506. PubMed ID: 19040326
[TBL] [Abstract][Full Text] [Related]
15. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study.
Maeda K; Takano J; Ikeda Y; Fujita T; Oyama Y; Nozawa K; Kumagai Y; Sugiyama Y
Clin Pharmacol Ther; 2011 Aug; 90(2):263-70. PubMed ID: 21716273
[TBL] [Abstract][Full Text] [Related]
16. Microdosing and drug development: past, present and future.
Lappin G; Noveck R; Burt T
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):817-34. PubMed ID: 23550938
[TBL] [Abstract][Full Text] [Related]
17. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
[TBL] [Abstract][Full Text] [Related]
18. Targeting intestinal transporters for optimizing oral drug absorption.
Varma MV; Ambler CM; Ullah M; Rotter CJ; Sun H; Litchfield J; Fenner KS; El-Kattan AF
Curr Drug Metab; 2010 Nov; 11(9):730-42. PubMed ID: 21189135
[TBL] [Abstract][Full Text] [Related]
19. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
Wagner CC; Langer O
Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
[TBL] [Abstract][Full Text] [Related]
20. Microdosing: current and the future.
Lappin G
Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
